Lantheus

Lantheus Holdings is a fully integrated radiopharmaceutical company that develops, manufactures, and commercializes radiodiagnostic and radiotherapeutic products — including PET imaging agents like PYLARIFY® for prostate cancer and DEFINITY® for echocardiography — along with AI-powered digital imaging tools, primarily serving oncology, cardiology, and neurology. The company is expanding from medical imaging into novel radiotherapeutics and targeted radioligand therapies to help clinicians find, fight, and follow disease.